Antioxidant use in Friedreich ataxia

Lauren Myers; Jennifer M. Farmer; Robert B. Wilson; Lisa Friedman; Amy Tsou; Susan L. Perlman; Sub H. Subramony; Christopher M. Gomez; Tetsuo Ashizawa; George R. Wilmot; Katherine D. Mathews; Laura J. Balcer; David R. Lynch

doi:10.1016/j.jns.2007.10.008

Antioxidant use in Friedreich ataxia

Lauren Myers, Jennifer M. Farmer, Robert B. Wilson, Lisa Friedman, Amy Tsou, Susan L. Perlman, Sub H. Subramony, Christopher M. Gomez, Tetsuo Ashizawa, George R. Wilmot, Katherine D. Mathews, Laura J. Balcer, David R. Lynch

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.

Original language	English (US)
Pages (from-to)	174-176
Number of pages	3
Journal	Journal of the Neurological Sciences
Volume	267
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jns.2007.10.008
State	Published - Apr 15 2008

Keywords

Ataxia
Cerebellum
Clinical trial
Idebenone

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.jns.2007.10.008

Cite this

@article{8b607d7328534f40a1cb6634555b6edf,

title = "Antioxidant use in Friedreich ataxia",

abstract = "Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.",

keywords = "Ataxia, Cerebellum, Clinical trial, Idebenone",

author = "Lauren Myers and Farmer, {Jennifer M.} and Wilson, {Robert B.} and Lisa Friedman and Amy Tsou and Perlman, {Susan L.} and Subramony, {Sub H.} and Gomez, {Christopher M.} and Tetsuo Ashizawa and Wilmot, {George R.} and Mathews, {Katherine D.} and Balcer, {Laura J.} and Lynch, {David R.}",

year = "2008",

month = apr,

day = "15",

doi = "10.1016/j.jns.2007.10.008",

language = "English (US)",

volume = "267",

pages = "174--176",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Antioxidant use in Friedreich ataxia

AU - Myers, Lauren

AU - Farmer, Jennifer M.

AU - Wilson, Robert B.

AU - Friedman, Lisa

AU - Tsou, Amy

AU - Perlman, Susan L.

AU - Subramony, Sub H.

AU - Gomez, Christopher M.

AU - Ashizawa, Tetsuo

AU - Wilmot, George R.

AU - Mathews, Katherine D.

AU - Balcer, Laura J.

AU - Lynch, David R.

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.

AB - Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.

KW - Ataxia

KW - Cerebellum

KW - Clinical trial

KW - Idebenone

UR - http://www.scopus.com/inward/record.url?scp=39149111563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149111563&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2007.10.008

DO - 10.1016/j.jns.2007.10.008

M3 - Article

C2 - 17988688

AN - SCOPUS:39149111563

SN - 0022-510X

VL - 267

SP - 174

EP - 176

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Antioxidant use in Friedreich ataxia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this